Patient experience of living with cancer-associated thrombosis in Canada (PELICANADA) by Noble, Simon et al.
Res Pract Thromb Haemost. 2019;00:1–7.	 	 	 | 	1wileyonlinelibrary.com/journal/rth2
 
Received:	27	July	2019  |  Revised:	3	September	2019  |  Accepted:	19	September	2019
DOI: 10.1002/rth2.12274  
O R I G I N A L  A R T I C L E
Patient Experience of Living With Cancer‐Associated 
Thrombosis in Canada (PELICANADA)
Simon Noble MBBS, MD, FRCP1  |   Annmarie Nelson PhD1  |   Jill Scott RN2 |   
Anne Berger RN2 |   Karen Schmidt RN2 |   Parinita Swarnkar1 |    
Agnes Lee MD, MSc, FRCPC3
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial‐NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non‐commercial	and	no	modifications	or	adaptations	are	made.
©	2019	The	Authors.	Research and Practice in Thrombosis and Haemostasis	published	by	Wiley	Periodicals,	Inc	on	behalf	of	International	Society	on	Thrombosis	
and	Haemostasis.
1Marie	Curie	Palliative	Care	Research	
Centre,	Cardiff	University,	Cardiff,	Wales,	
UK
2Division	of	Hematology,	University	of	
British	Columbia,	Vancouver,	BC,	Canada
3Division	of	Hematology,	University	of	
British	Columbia,	British	Columbia	Cancer	
Agency,	Vancouver,	BC,	Canada
Correspondence
Simon	Noble,	Marie	Curie	Palliative	Care	
Research	Centre,	8th	Floor,	Neuadd	
Meirionydd,	Cardiff	University,	Heath	Park	
Campus,	CF14	4YS,	Wales,	UK.
Email:	NobleSI1@cardiff.ac.uk
Funding information
LEO	Pharma	Research	Foundation
Handling	Editor:	Neil	Zakai
Abstract
Introduction: Previous	research	from	the	United	Kingdom	and	Spain	has	identified	
several	areas	of	unmet	clinical	and	support	need	for	cancer	patients	diagnosed	with	
venous	thromboembolism.	It	is	not	known	whether	such	experiences	are	restricted	
to	those	countries	health	care	systems	and	culture.	We	therefore	evaluated	patients’	
experience	of	cancer‐associated	thrombosis	(CAT)	within	a	Canadian	setting.
Methods: Purposive	sampling	of	patients	with	CAT	attending	a	regional	thrombosis	
clinic	in	Vancouver	was	undertaken.	Semistructured	interviews	were	audio	recorded,	
transcribed,	and	coded	using	NVivo	software.	A	deductive	approach	was	taken	by	
applying	the	framework	matrix	from	the	original	study	to	these	data	on	a	case‐by‐
case	basis.
Results: Twenty	patients	(10	male,	10	female)	aged	39	to	74	(mean,	63)	represent‐
ing	a	breadth	of	different	cancers	participated.	Commonalities	between	the	UK	and	
Canadian	patients	included	the	traumatic	nature	of	experiencing	CAT,	the	need	for	in‐
formation,	and	adaptive	behaviors	through	ritualization.	Two	new	themes	were	iden‐
tified:	 (1)	Patients	with	 incidental	pulmonary	emboli	 (iPE)	were	usually	 telephoned	
about	their	thrombus	with	little	support	and	suboptimal	communication;	and	(2)	cost	
implications	of	accessing	low‐molecular‐weight	heparin	varied	according	to	insurance	
cover.	Patients	were	sometimes	converted	to	warfarin	for	financial	reasons.
Conclusion: The	distress	associated	with	CAT	is	a	common	experience	across	differ‐
ent	populations	but	may	be	ameliorated	by	early	access	to	specialist	services,	infor‐
mation,	and	support.	The	current	process	for	managing	iPE	could	be	improved	with	
better	communication	and	a	dedicated	clinical	pathway.	Funding	issues	may	influence	
choice	of	anticoagulant.
K E Y W O R D S
cancer‐associated	thrombosis,	cultural,	patient	experience,	qualitative,	venous	
thromboembolism
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1  | INTRODUCTION
Venous	thromboembolism	(VTE),	comprising	deep	vein	thrombosis	
(DVT)	 and	pulmonary	 embolus	 (PE),	 is	 a	major	 cause	of	morbidity	
and	mortality	among	cancer	patients.1	The	 incidence	of	cancer‐as‐
sociated	thrombosis	(CAT),	a	thrombotic	event	occurring	in	someone	
known	to	have	cancer,	will	vary	according	to	primary	cancer,	stage,	
and	treatments,	but	overall	it	affects	approximately	20%	of	cancer	
patients	during	their	lifetime.2	The	past	decade	has	seen	a	growing	
understanding	of	the	psychological	impact	of	VTE	in	both	the	can‐
cer	and	noncancer	setting.3	Qualitative	studies	have	suggested	that	
some	patients	experience	persistent	anxiety	following	a	VTE,	which	
is	 independent	 of	 the	 severity	 or	 clot	 burden	 of	 the	 thrombotic	
event.3,4	Some	may	develop	what	has	been	termed	postthrombotic 
panic syndrome	 with	 persistent	 symptoms	 meeting	 the	 diagnostic	
criteria	for	posttraumatic	stress	disorder.5
Studies	initially	undertaken	to	evaluate	the	experiences	of	CAT	
patients	 of	 self‐injecting	 low‐molecular‐weight	 heparin	 (LMWH),	
identified	 a	 significant	 level	 of	 distress	 and	 anxiety	 associated	
with	 patients’	 experience	 and	 perceived	 meaning	 of	 CAT.6,7 The 
Patient	Experience	of	 Living	With	Cancer‐Associated	Thrombosis	
(PELICAN)	study	was	a	qualitative	study,	conducted	in	the	United	
Kingdom	to	evaluate	the	impact	of	VTE	on	20	cancer	patients	and	
their	extended	family.8	The	study	confirmed	CAT	to	be	a	distress‐
ing	 experience,	 with	 limited	 support	 or	 information,	 in	 complete	
juxtaposition	 with	 the	 treatment	 they	 received	 for	 their	 cancer.	
Patients	 felt	 there	 was	 little	 health	 care	 professional	 ownership	
for	the	management	of	CAT,	which	further	added	to	their	distress.	
More	recently,	a	similar	study	using	identical	methodology,	Patient	
Experience	of	Living	With	Cancer‐Associated	Thrombosis	in	Spain	
(PELICANOS),	 was	 reported	 from	 Spain;	 a	 country	with	 a	 similar	
model	of	 central	 government–funded	health	 care	delivery	 to	 that	
seen	in	the	United	Kingdom.9	It	followed	a	similar	methodology	to	
PELICAN,	interviewing	20	patients	and	using	framework	analysis.8 
Several	commonalities	between	the	UK	and	Spanish	patients	were	
identified,	 including	the	traumatic	nature	of	being	diagnosed	with	
CAT,	the	need	for	 information,	and	adaptive	behaviors	around	 in‐
jecting	their	LMWH	through	ritualization.	However,	the	degree	of	
anxiety	observed	in	the	Spanish	cohort	was	greater	than	that	ob‐
served	in	the	UK	cohort,	and	this	level	of	distress	extended	to	the	
immediate	family,	whose	needs	sometimes	took	primacy	over	 the	
patient.
While	 the	experience	of	CAT	may	vary	according	 to	culture,	 it	
is	not	known	whether	there	are	also	variances	according	to	health	
care	systems.	Health	care	provision	in	Canada	differs	from	the	social	
security–funded	national	health	care	system	in	Spain	and	the	United	
Kingdom.	The	Canadian	system	consists	of	13	provincial	and	terri‐
torial	health	 insurance	plans	 that	provide	health	care	coverage	on	
a	provincial	or	territorial	basis,	within	guidelines	set	by	the	federal	
government.	Approximately	70%	of	health	care	expenditure	comes	
through	 public	 funding,	with	 the	 remainder	 covered	 by	 health	 in‐
surance	 and	 individual	 payments.10	 Approximately	 two‐thirds	 of	
Canadians	hold	private	health	insurance	to	cover	services	excluded	
from	public	reimbursement	such	as	prescription	medicines,	including	
anticoagulants.
We	 therefore	 undertook	 a	 study	 to	 explore	 the	 Patient	
Experience	of	Living	With	Cancer‐Associated	Thrombosis	in	Canada	
(PELICANADA),	specifically	of	those	living	in	the	province	of	British	
Columbia.	Within	this	province,	 the	Medicare	program	 is	provided	
by	 the	 government‐administered	Medical	 Services	 Plan	 of	 British	
Columbia,	for	which	residents	are	required	to	submit	monthly	premi‐
ums.	Selected	prescription	drug	costs,	including	LMWH,	are	partially	
subsidized	based	on	annual	family	income.
Specifically,	the	study	aims	were	to	explore:
•	 The	journey	of	CAT	patients	through	lived	patient	experience
•	 The	meaning	of	CAT	to	patients	within	the	context	of	the	cancer	
journey
•	 The	impact	of	the	treatment	for	CAT
•	 The	emotional	impact	of	CAT
•	 Information	needs	for	patients
2  | METHODS
2.1 | Data collection
The	methods	have	been	described	 in	detail	previously.8	Purposive	
sampling	 of	 patients	 attending	 a	 thrombosis	 outpatient	 service	 at	
a	university‐affiliated	teaching	hospital,	which	serves	a	population	
of	2.3	million,	were	sequentially	screened	for	inclusion	in	the	study.	
Screening	was	 undertaken	 by	 experienced	 thrombosis	 nurses	 (JS,	
AB,	 and	 KS),	 who	 also	 approached	 eligible	 patients	 face	 to	 face.	
Where	patients	attended	with	their	partner	or	next	of	kin,	they	were	
also	given	an	opportunity	to	be	interviewed.
English‐speaking	 participants	 were	 eligible	 if	 they	 had	 histo‐
logically	 confirmed	 cancer,	 had	 been	 receiving	 anticoagulation	
for	proven	new	DVT	or	PE	for	at	 least	2	months	and	were	able	to	
consent	to	a	40‐minute	interview.	They	were	ineligible	if	they	had	
nonmelanoma	skin	cancer,	the	thrombosis	predated	their	cancer	di‐
agnosis,	or	they	were	unable	to	participate	in	a	40‐minute	interview.
Essentials
•	 The	impact	of	venous	thromboembolism	(VTE)	on	Canadian	cancer	patients	is	unknown.
•	 A	qualitative	study	was	undertaken	to	explore	the	impact	of	cancer‐associated	VTE	on	patients	living	in	Vancouver.
•	 The	diagnosis	and	management	of	incidental	pulmonary	emboli	is	associated	with	significant	patient	distress.
•	 Anticoagulant	prescribing	may	be	influenced	by	patients’	financial	or	socioeconomic	status.
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All	participants	provided	 informed	written	consent.	Each	 inter‐
view	was	 individually	 conducted	by	1	of	3	 researchers	 (JS,	AB,	or	
KS).	 In	 total,	 20	 qualitative	 interviews	 were	 undertaken	 between	
July	2015	and	March	2016.
Participants	were	receiving	treatment	at	the	hospital	where	the	
interviewers	worked;	however,	the	interviewers	did	not	have	access	
to	medical	records	beyond	collecting	demographic	data.
While	 interviewers	approached	the	 interviews	with	knowledge	
of	the	UK	PELICAN	study,	they	had	no	fixed	beliefs	or	bias	with	re‐
gard	to	cultural	differences	and	no	knowledge	of	the	Spanish	data.	
The	patients	received	an	information	leaflet	outlining	the	aims	of	the	
study	but	had	no	identified	preinterview	agenda.	The	interviewers	
were	 experienced	 in	 communication	 skills	 but	were	 new	 to	 quali‐
tative	interviewing.	They	received	interview	training	from	the	chief	
investigator	 (SN)	 and	 undertook	 pilot	 interviews	 with	 feedback.	
Interviews	were	audio	recorded	and	transcribed	verbatim.	The	chief	
investigator	 reviewed	 each	 interview,	 and	 feedback	 was	 given	 to	
further	hone	the	interviewer's	skills.	Interviews	were	conducted	at	
the	preferred	 location	of	 the	patient:	either	 the	patient's	home	or	
a	hospital	outpatient	clinic.	Questions	were	guided	by	an	interview	
schedule	 (see	supplementary	material)	 to	ensure	 that	 the	same	 is‐
sues	were	discussed	at	each	interview.
Data	were	elicited	on	the	following:
•	 Patients’	and	caregivers’	experience	of	being	diagnosed	with	CAT
•	 The	physical	and	emotional	impact	of	CAT	and	its	treatment
•	 How	patient	care	could	be	improved
To	 facilitate	 this,	 questions	 were	 open‐ended,	 with	 the	 use	 of	
prompts	 to	 probe	 further	 into	 issues	 that	 arose	 as	 significant	 or	
meaningful	 to	 the	participant.	 Interviews	were	 recorded	and	tran‐
scribed	verbatim.	Field	notes	were	also	taken	as	required.	Transcripts	
were	available	for	participants	to	check	and,	where	necessary,	rec‐
ommend	amendments.
2.2 | Analysis
Transcripts	 were	 typed	 into	 a	 Word	 document,	 and	 data	 were	
managed	 using	 NVivo	 10	 computer	 software	 (QSR	 International,	
Melbourne,	 Australia).11	 Any	 identifying	 information	 was	 an‐
onymized.	Data	analysis	was	undertaken	using	Framework	Analysis	
as	 per	 the	 previous	 study	 using	 Richie	 and	 Spencer's	 5	 intercon‐
nected	 stages,	 namely:	 familiarization	 with	 data,	 identifying	 a	
thematic	framework	indexing	the	data,	charting,	mapping,	and	inter‐
pretation.12	This	method,	known	as	coding,	is	the	process	of	naming,	
labeling,	and	sorting	data,	which	enables	researchers	to	find	emerg‐
ing	themes	or	patterns.	However,	a	pragmatic	approach	was	used,	
with	an	applied	framework	matrix	and	codes	from	the	original	study	
on	a	case‐by‐case	basis	using	a	deductive	approach.	If	there	was	no	
evidence	of	a	particular	code,	this	field	was	left	blank	in	order	to	take	
an	overview	of	the	commonalities	and	missing	codes	from	the	data	
set.	For	the	next	stage,	all	of	the	remaining	uncoded	data	were	ana‐
lyzed	with	an	inductive	approach	to	establish	a	new	set	of	themes.	
This	 was	 done	 in	 order	 to	 explicate	 potential	 cultural	 and	 opera‐
tional	differences	that	were	not	apparent	in	the	UK	and	Spanish	data	
sets.	An	 independent	 researcher	with	 no	prior	 knowledge	of	CAT	
(PS)	undertook	primary	coding,	and	this	was	the	verified	by	2	sen‐
ior	researchers	(SN	and	AN).	A	preagreed	number	of	20	interviews	
was	planned,	 in	keeping	with	 the	original	PELICAN	study,	with	an	
option	to	continue	recruitment	if	theoretical	saturation	(ie,	no	new	
themes	were	emergent),	as	assessed	by	the	researcher,	had	not	been	
reached.
3  | RESULTS
Research	 ethics	 approval	 was	 obtained	 from	 the	 University	 of	
British	Columbia	BC	Cancer	Research	Ethics	Board	(H14‐01898)	
before	 study	 enrollment.	 Twenty	 patients	 agreed	 to	 partici‐
pate,	 and	 their	 clinical	 characteristics	 are	 recorded	 in	 Table	 1.	
Three	patients	who	were	approached	declined	to	participate	but	
gave	 no	 reason.	 No	 interviews	 needed	 repeating,	 and	 no	 par‐
ticipants	requested	transcripts	to	review.	Theoretical	saturation	
was	 reached	 at	 14	 interviews,	 when	 no	 new	 themes	 were	 ap‐
parent.	The	3	major	themes	previously	identified	in	the	original	
PELICAN	 and	 PELICANOS	 studies	 were	 also	 observed	 in	 this	
data	 set,	 namely,	 the	 distressing	 experience	 of	 CAT,	 informa‐
tion	 requirements,	 and	 adaptive	 behaviors/ritualization8,9. In 
addition,	 2	 new	 themes	 emerged:	 incidental	 pulmonary	 emboli	
and	 the	 cost	 implications	 of	 LMWH.	 These	 are	 summarized	 in	
Figure	1.	Each	theme	is	discussed	below	with	its	associated	sub‐
themes.	 Themes	 are	 supported	 by	 patient	 quotes,	 which	were	
chosen	according	 to	2	 criteria:	 They	 illustrate	 the	 theme	being	
discussed,	and	they	represent	a	breadth	of	data	across	as	many	
participants	as	possible.
3.1 | Previously identified theme: Traumatic 
nature of CAT
Previous	 studies	 have	 highlighted	 the	 distress	 experienced	by	 pa‐
tients	when	diagnosed	with	CAT.	The	impact	on	Canadian	patients	
appeared	no	different.
I	cried.	All	the	time	I	cried…I	was	an	emotional	wreck.	
100‐02
For	some,	the	experience	of	CAT	was	more	distressing	than	the	
cancer	diagnosis	itself.	Previous	research	suggested	this	was	due	to	
either	a	distressing	symptom	burden	or	the	rushed	diagnostic	pro‐
cess.	 In	 PELICANADA,	 patients	 found	 the	 delivery	 of	 the	 diagno‐
sis	of	CAT	to	be	rushed,	and	the	fact	that	CAT	was	potentially	 life	
threatening	exacerbated	their	distress.
Well,	 at	 first	 it	made	me	 feel	 that	my	 health	 issues	
were	even	more	terminal	than	the	cancer	originally.	
100‐03
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3.2 | Previously identified theme: Information needs
Patients	 identified	2	main	areas	of	 information	need.	First,	 lack	of	
forewarning	regarding	the	risk	of	clots	and	possibility	of	death	was	
a	significant	driver	of	distress.	They	also	worried	regarding	the	un‐
certainty	of	whether	 a	 clot	may	 recur.	Patients	 felt	 that	 adequate	
forewarning	and	information	would	help	ameliorate	this.
The	blood	clot	was	a	scary	thing	because	I	didn’t	know	
if	 I	 should	 have	 been	 looking	 for	 something	 and	 from	
what	 questions	 I	 have	 been	 asked,	 there	was	 nothing	
that	would	have	alerted	me.	…	Because	knowing	nothing	
about	clots,	it	just	meant	almost	like	a	death	sentence.	
100‐10
Second,	information	was	needed	regarding	the	administration	
of	LMWH,	which	patients	were	often	required	to	do	themselves.	
Some	patients	acknowledged	receiving	information	on	how	to	in‐
ject	but	reported	that	this	was	often	difficult	to	understand.
When	I	got	the	box	of	syringes,	there	was	a	very	ex‐
tensive	description	of	what	to	do;	however,	…	the	de‐
scription	of	how	to	manipulate	this	 little	syringe	was	
not	as	clear	as	it	could	be	and	…	I	almost	had	to	figure	it	
out	on	my	own	with	the	pharmacist	on	how	to	manipu‐
late	the	needle	and	how	to	cover	it	back	up	and	so	on.	
100‐03
Some	 patients	 received	 no	 information	 on	 how	 to	 inject,	which	
often	led	to	poor	technique	and	associated	complications.
My	stomach	was	so	bruised	 that	 I	didn’t	do	 the	 top	
part	of	my	belly	because	nobody	ever	told	me	(to	do)	
the	 top	 part.	 They	 didn’t	 give	me	 a	 program,	 like	 a	
sheet	that	says,	you	know,	there	 is	the	top	part	and	
you	go	over	to	the	side,	2	inches	here,	2	inches	there,	
2	inches	here,	around	the	belly	button.	
100‐02
3.3 | Previously identified theme: 
Acceptability of LMWH
The	majority	of	patients	received	the	anticoagulant	LWMH,	which	
required	a	daily	subcutaneous	injection.	As	with	previous	research,	
most	patients	found	the	injections	an	acceptable	intervention	within	
the	context	of	their	cancer	journey.
TA B L E  1  Characteristics	of	study	participants
Code Age
Sex
M/F Cancer diagnosis Disease status
VTE 
details Rx
Length of 
Rx (mo) Admin
100‐1 65 M Myeloma Palliative DVT WarfarinLMWH 12 Self
100‐2 62 F Lung Post	curative	resection PE LMWH 9 Self
100‐3 72 M Metastatic	Prostate Palliative iPE LMWH 5 Self
100‐4 74 M Prostate Curative iPE LMWH 12 Self
100‐5 68 F Metastatic	Breast Palliative iPE LMWH 7 Self
100‐8 62 F Metastatic	Ovarian Palliative PE LMWH 9 Self
100‐9 55 F Metastatic	colorectal Palliative Stroke LMWH 8 Self
100‐10 71 F Chronic	Lymphocytic	
Leukemia
Post	stem	cell	transplant iPEiDVT LMWH 5 Self
100‐11 69 F Renal cell carcinoma Palliative iDVT Warfarin 11 Self
100‐12 68 F Metastatic	breast Palliative PE LMWH 6 Self
100‐13 49 M Metastatic	colorectal Palliative PE LMWH 14 Self
100‐14 67 M Gastric Metastatic PEDVT LMWH 3 Self
100‐15 65 F Breast Metastatic PE LMWH 4 Wife
100‐16 68 F Bladder Curative DVT LMWH 9 Daughter
100‐17 69 M Myeloma Post	stem	cell	transplant DVT LMWH 5 Self
100‐18 70 F Acute	myeloid	leukemia In	remission PE LMWH 6 Husband
100‐19 48 F Metastatic	ovarian Palliative iPE LMWH 6 Self
100‐20 63 F Myeloma In	remission,	on	maintenance	
treatment
DVT LMWH 8 Husband
100‐21 39 M Acute	myeloid	leukemia Post	stem	cell	transplant DVT LMWH 4 Self
100‐22 58 F Brain Inoperable,	palliative	chemo DVT LMWH 6 Self
DVT,	deep	vein	thrombosis;	iDVT,	incidental	deep	vein	thrombosis;	iPE,	incidental	pulmonary	embolus;	LMWH,	low‐molecular‐weight	heparin;	PE,	
pulmonary	embolus;	VTE,	venous	thromboembolism.
     |  5NOBLE Et aL.
I	have	accepted	it	as	a	part	of	treatment.	It	 is	some‐
thing	I	have	no	choice.	
100‐01
Patients	 and	 caregivers	 were	 willing	 to	 learn	 to	 self‐inject,	
since	 it	 gave	 them	more	 freedom	and	 removed	 the	 need	 to	 at‐
tend	the	hospital	for	an	injection	or	wait	at	home	for	a	homecare	
nurse.
I	knew	that	injecting	myself	was	much	easier	for	me	
than	 going	 to	 the	 hospital	 and	 have	 somebody	 else	
taking	all	the	trouble	of	coming,	so	I	tried	to	learn	it.	
…	Administering	this	is	so	easy.	I	did	myself	because	it	
wasn’t	worth	going	back	and	forth.	Since	then,	I	have	
been	doing	it	myself.
100‐01
In	keeping	with	other	studies,	patients	would	normalize	the	pro‐
cess	of	self‐injecting	by	developing	habits	and	rituals.	Some	saw	the	
process	as	heralding	the	beginning	of	the	day.
We	 have	 our	 coffee	 and	 our	muffin	 in	 the	morning	
and	it’s	time	for	my	shot.	We	do	it	every	day.	…	Then	I	
hold	it	there,	hold	the	little	pad	over	it	and,	for	about	
5	minutes,	 have	my	 second	 cup	of	 coffee	 and	done	
for	the	day.	
100‐04
I	 do	 it	 in	 the	 morning,	 and	 then	 I	 am	 good	 for	 the	
whole day. 
100‐05
3.4 | New theme: Incidental PE
Incidental	 pulmonary	 emboli	 (iPE)	 are	 clots	 that	 are	 diagnosed	on	
imaging	ordered	for	indications	other	than	PE.	These	usually	occur	
when	 staging	 a	 newly	 diagnosed	 cancer	 or	 when	 evaluating	 re‐
sponse	to	treatment.	Generally,	these	patients	do	not	spontaneously	
volunteer	 symptoms	 suggestive	 of	 PE,	 although	 direct	 question‐
ing	may	reveal	a	degree	of	symptom	burden.	Six	patients	 (100‐03,	
100‐04,	100‐05,	100‐10,	100‐11,	and	100‐19)	were	diagnosed	with	
iPE,	which	differs	considerably	from	the	PELICAN	study	(n	=	2)	and	
PELICANOS	(n	=	0).	Their	experiences	offer	a	different	insight	into	
the	experience	of	CAT	than	those	presenting	with	symptoms.
Patients	usually	received	the	diagnosis	of	PE	over	the	telephone,	
when	they	were	asked	to	come	in	to	the	hospital	as	a	matter	of	urgency.
Actually,	we	had	finished	an	appointment	at	the	hos‐
pital	and	we	were	on	our	way	home,	and	we	stopped	
for	coffee	at	Starbucks	for	our	daughter	and	then	we	
got	 a	 phone	 call	 and	 said	 you	 better	 get	 back	 here	
quick	sort	of	thing,	said	they	discovered	a	clot.	
100‐10
Sometimes	patients	would	have	only	recently	attended	the	hos‐
pital	and	were	reluctant	to	come	back	in.	This	would	result	in	their	
being	informed	that	they	had	a	potentially	life‐threatening	condition	
that	could	result	in	death	if	they	did	not	return	immediately.
It	was	a	big	deal	when	it	was	first	discovered.	Because	
remember	she	said	you	got	to	come	in	now.	
100‐05
And	the	doctor	phones	and	says	you	better	get	in,	it’s	
life	threatening.	
100‐04
Despite	being	informed	that	their	condition	was	potentially	life	threat‐
ening	 and	needed	 immediate	hospital	 attendance,	 some	patients	 found	
that	the	sense	of	urgency	did	not	continue	when	they	presented	to	the	hos‐
pital.	This	was	most	apparent	for	those	who	attended	the	emergency	unit:	
Patients	reported	that	there	was	no	sense	of	urgency	when	triaged	and	
graded	as	low	priority.	This	conflicting	juxtaposition	of	urgency	from	those	
asking	the	patient	to	attend	the	hospital	and	the	indifference	from	those	
receiving	them	created	an	additional	cause	for	disquiet	and	confusion.
We	went	to	emergency,	and	we	sat	there	and	waited	
and waited. 
100‐3
3.5 | New theme: Access to medicines
The	cost	of	 LMWH	for	 the	 treatment	of	CAT	was	covered	by	 the	
provincial	 health	 care	plan	 (PharmaCare)	 for	 periods	of	 6	months,	
F I G U R E  1  Previously	identified	themes	and	new	themes
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renewable	as	long	as	the	patient	continued	to	have	active	cancer	and	
needed	anticoagulation.13	However,	each	patient	is	responsible	for	
paying	for	their	drug	deductible	each	calendar	year	before	the	cost	
of	drugs	is	covered	by	the	government.	This	deductible	is	dependent	
on	their	personal	and	family	income,	so	some	patients	are	still	paying	
out	of	pocket	or	are	covered	by	private	health	insurance	even	with	
PharmaCare	 coverage.	 Where	 patients	 did	 not	 have	 appropriate	
health	 insurance,	 they	would	often	 incur	additional	 financial	 costs	
to	remain	on	LMWH.
I	still	don’t	have	my	PharmaCare	in	place,	so	yah,	I	am	
paying	for	[LMWH].	I	am	paying	for	a	lot	of	things.	So	
when	 I	 go	 to	 the	 pharmacy	 about	 once	 a	month	 or	
every	other	month,	I	drop	about	a	$500	bill	because	
I	accumulate	so	I	don’t	have	to	go	back	there	all	the	
time. 
100‐05
Some	patients	not	covered	by	insurance	would	be	converted	from	
LMWH	to	a	cheaper	anticoagulant,	warfarin,	which	was	known	to	be	
less	efficacious.
First,	 the	doctor	talked	to	me.	Then,	 they	came	and	
talked	 to	me	 about	 the	warfarin,	 and	 they	 gave	me	
some	leaflets.	
100‐11
4  | DISCUSSION
The	PELICANADA	study	sought	to	explore	the	experiences	of	can‐
cer	patients	in	Vancouver	who	had	been	diagnosed	with	VTE.	Data	
from	 the	 United	 Kingdom	 and	 Spain	 have	 identified	 CAT	 to	 be	 a	
distressing	 experience	 and	 one	 for	which	 patients	 receive	 limited	
information	or	support.	These	findings	concurred	with	Canadian	pa‐
tients’	experiences.	This	study	also	identified	2	important	new	areas	
of	 interest,	namely,	the	 impact	of	health	care	funding	on	prescrib‐
ing	practices	and	the	challenge	of	managing	iPE	without	increasing	
patient	distress.
The	diagnosis	of	iPE	usually	occurs	at	a	time	of	heightened	anx‐
iety	 for	 the	 patient	 because	 imaging	was	 ordered	 either	 to	 stage	
a	 recently	 diagnosed	 new	 cancer	 or	 to	 assess	 response	 to	 recent	
treatment.	As	previous	studies	have	 illustrated,	one	of	 the	drivers	
of	 distress	 around	 CAT	 is	 living	 with	 a	 potentially	 fatal	 condition	
that	carries	an	ongoing	risk	of	recurrence.7‒9	Breaking	the	news	to	
a	cancer	patient,	already	contemplating	their	mortality	while	wait‐
ing	 anxiously	 for	 their	 staging	 results,	 that	 they	 have	 developed	
another	potential	threat	to	life	should	be	afforded	the	same	sensi‐
tive	approach	of	any	other	breaking	bad	news	scenario.	In	practice,	
this	 rarely	happens;	 instead,	 learning	 the	 findings	 from	a	stranger,	
by	 telephone,	without	 the	benefit	of	a	 supportive	environment	or	
customary	approach	to	breaking	bad	news,	is	the	norm.	Patients	re‐
luctant	 to	 come	 to	 the	 hospital	were	often	 advised	 that	 the	 clots	
could	be	life	threatening,	thereby	adding	to	distress	and	also	gener‐
ating	expectations	for	their	arrival	at	the	hospital.	Having	responded	
to	the	urgency	of	their	condition,	patients	would	be	perplexed	that	
their	presentation	was	rarely	greeted	with	a	sense	of	urgency	and	in	
complete	contrast	to	the	advice	and	information	given	by	telephone.	
These	data	make	a	strong	case	for	the	development	and	implemen‐
tation	 of	 a	 clinical	 pathway	 for	 the	 diagnosis	 and	management	 of	
iPE,	which	 includes	 consideration	of	 information	delivery	with	 re‐
spect	to	both	diagnosis	of	the	PE	and	its	ongoing	management.	Such	
pathways	 do	 exist	 but	 arguably	 should	 be	 a	minimum	 standard	 in	
CAT	management.14	 It	 is	 important	 to	note	 that	 the	 issues	around	
the	diagnosis	of	iPE	are	probably	not	specific	to	Canada;	it	is	more	
likely	 a	 reflection	of	 the	numbers	of	 iPE	patients	 in	PELICAN	and	
PELICANOS	being	 too	 low	for	any	meaningful	 signal	 to	emerge	 in	
isolation.	Furthermore,	 given	 that	PE	occurs	 in	3.6%	of	 all	 staging	
computed	tomography	scans	and	accounts	for	40%	of	all	cancer‐as‐
sociated	PE,	management	of	this	unexpected	outcome	is	a	common	
and	important	clinical	scenario.15,16
This	is	the	first	of	the	PELICAN	studies	to	suggest	that	the	type	
of	health	care	 funding	may	 impact	on	which	anticoagulant	 is	used	
to	treat	CAT.	Furthermore,	it	infers	that	patients	of	lower	socioeco‐
nomic	status	(ie,	those	without	health	insurance	or	sufficient	funds)	
are	less	likely	to	receive	the	current	gold	standard	treatment.	This	is	
unsurprising;	and	American	data	from	2941	newly	diagnosed	CAT	pa‐
tients	observed	that	the	majority	were	anticoagulated	with	warfarin	
(47.7%),	with	the	remainder	receiving	LMWH	(25%)	and	rivaroxaban	
(24.1%).17	 In	 an	earlier	observational	 study,	only	19%	of	American	
patients	with	CAT	received	LMWH	first	line,	and	81%	warfarin.	The	
most	common	 reason	given	by	patients	 receiving	warfarin	 (49.4%)	
was	 that	 their	medical	 insurance	did	not	cover	 the	cost	of	LMWH	
and	they	could	not	afford	the	out‐of‐pocket	expenditure.	This	is	the	
first	data	set	from	the	PELICAN	studies	to	highlight	nonuniformity	
of	care	due	to	different	health	funding	structure.	It	was	beyond	the	
remit	of	this	study	to	follow	up	patients’	long‐term	incidence	of	re‐
current	thrombosis	and	bleeding,	but	it	is	plausible	that	such	inequal‐
ities	in	health	provision	could	lead	to	different	outcomes.
As	with	 all	 studies,	 it	 is	 important	 to	 consider	 the	 data	within	
the	context	of	the	study	limitations.	Interviews	were	conducted	by	
3	 researchers	 (JS,	AB,	 and	KS),	which	could	potentially	 lead	 to	 in‐
consistency	 in	 interview	 styles	 and	 questions	 asked.	 Every	 effort	
was	undertaken	to	minimize	this,	including	feedback	where	needed	
and	independent	review	of	data	to	ensure	consistency.	It	is	also	im‐
portant	to	acknowledge	that	Canada	is	a	vast	country	with	different	
health	systems	and	even	cultures	across	the	different	provinces	and	
territories.	As	interviews	were	conducted	in	only	one	province,	the	
degree	to	which	these	findings	can	be	generalized	is	unclear.	Finally,	
it	 is	 important	 to	 recognize	 that	 at	 the	 time	 interviews	were	 con‐
ducted,	the	direct‐acting	oral	anticoagulants	were	rarely	used	in	the	
treatment	of	CAT,	and	as	their	use	becomes	more	widespread,	the	
experience	of	CAT	for	Canadian	patients	may	change.	Nevertheless,	
these	data	support	 findings	from	previous	countries,	 including	the	
distress	of	experiencing	CAT,	the	need	for	 information	at	the	time	
of	 CAT	 diagnosis,	 and	 acceptability	 of	 LMWH.	 The	 emergence	 of	
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new	themes,	particularly	 those	 influenced	by	differing	health	care	
systems	to	those	in	previous	studies,	justifies	further	evaluation	of	
patient	experiences	in	other	countries.
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